[A19-25] Abemaciclib (breast cancer; combination with fulvestrant) - Addendum to Commission A18-73
Last updated 02.05.2019
Commission awarded on 11.03.2019 by the Federal Joint Committee (G-BA).
Women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Conclusion of dossier assessment A18-73 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.